Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tolebrutinib by Sanofi for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval
Tolebrutinib is under clinical development by Sanofi and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS). According to...
Risk adjusted net present value: What is the current valuation of Sanofi's Tolebrutinib?
Tolebrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Secondary Progressive Multiple Sclerosis (SPMS)....
Risk adjusted net present value: What is the current valuation of Sanofi's Tolebrutinib?
Tolebrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Primary Progressive Multiple Sclerosis (PPMS)....